Kevin M. Cottrell - Concepedia

Author

Kevin M. Cottrell

Vertex Pharmaceuticals (United States)ORCID

Also Known As

K. Cottrell, K.M. Cottrell, Kevin Cottrell, Kevin M Cottrell, Kevin M. Cottrell

Publications

691

Citations

H-Index

Concepts

All Affiliations

Vertex Pharmaceuticals (United States)Tango Therapeutics (United States)Vertex Pharmaceuticals (Canada)

About

Kevin M. Cottrell is an author at Vertex Pharmaceuticals (United States) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	216
2	Natural Sciences	5	5	147
3	Biochemistry	5	5	147
4	Biomolecular Engineering	1	1	17
5	Chemical Biology	1	1	31

Kevin M. Cottrell

Publications

622

Citations

H-Index

Page 1

	Year	Citations
In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061 Chao Lin, Kai Lin, Yu-Ping Luong, Journal of Biological Chemistry	2004	289
Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with <i>MTAP</i>-Deleted Cancers Kevin M. Cottrell, Kimberly J. Briggs, Douglas A. Whittington, Journal of Medicinal Chemistry	2024	58
Inhibitors of hepatitis C virus NS3·4A protease. Part 3: P2 proline variants Robert B. Perni, Luc J. Farmer, Kevin M. Cottrell, Bioorganic & Medicinal Chemistry Letters Viral HepatitisAntiviral Drug DevelopmentAntiviral TherapyHepatitisVirology	2004	52
Structural Basis for Isoform Selectivity in a Class of Benzothiazole Inhibitors of Phosphoinositide 3-Kinase γ Philip N. Collier, Gabriel Martínez-Botella, Mark Cornebise, Journal of Medicinal Chemistry Drug TargetMolecular BiologyMolecular PharmacologyMedicinal ChemistrySelective Benzothiazole Inhibitors	2014	51
Synthesis and enzymatic evaluation of a P1 arginine aminocoumarin substrate library for trypsin-like serine proteases Philip D. Edwards, Russell C. Mauger, Kevin M. Cottrell, Bioorganic & Medicinal Chemistry Letters Protease InhibitorsProtein ChemistryBiochemistryProtein FoldingMedicine	2000	38
Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ Philip N. Collier, David Messersmith, Arnaud LeTiran, Journal of Medicinal Chemistry Molecular DockingMolecular PharmacologyPi3k Isoform SelectivityPhosphoinositide 3-KinasePi3kγ Selectivity	2015	31
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with <i>MTAP</i> Deletion Kevin M. Cottrell, Kimberly J. Briggs, Alice Tsai, Journal of Medicinal Chemistry	2025	20
Inhibitors of hepatitis C virus NS3·4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics Robert B. Perni, Gurudatt Chandorkar, Kevin M. Cottrell, Bioorganic & Medicinal Chemistry Letters Viral HepatitisMedicineAntiviral Drug DevelopmentAntiviral TherapyHepatitis	2007	17
TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers Kimberly J. Briggs, Kevin M. Cottrell, Matthew R. Tonini, Translational Oncology	2025	16
Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors Simon Giroux, Jinwang Xu, T. Jagadeeswar Reddy, ACS Medicinal Chemistry Letters Combinatorial ChemistryHeterocycle ChemistryAntiviral DrugPharmaceutical ChemistryMedicinal Chemistry	2013	14

Page 1